MEDICATION USE EVALUATION CRITERIA
Antiemetic Use in the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting
Request for Approval by Medication Use Evaluation Committee
Purpose of evaluation: The purpose of this Medication Use Evaluation (MUE) is to evaluate the use of antiemetic therapy in the prevention of chemotherapy-induced nausea and vomiting. This agent was selected for evaluation based on its essential role in the management of this patient population, potential inappropriate use, and increased cost relative to other antiemetic agents. This class of medications has not been evaluated within the organization for at least 5 years.
Criteria: A multidisciplinary group including physicians, clinical nurse specialists, staff nurses from the oncology unit, and pharmacists developed the attached criteria. They are submitted for approval by the MUE Committee.
Data Collection: Data will be collected on all patients with orders for this agent written throughout a period of approximately 30 days beginning in mid-January 20XX. A minimum of 50 cases will be reviewed. Pharmacists and clinical nurse specialists will collect data concurrently from the medical record. Patients will be identified by means of the clinical information system.
Results: Results will be presented to this Committee. Information will also be shared with the Cancer Care Committee and Health system Performance Improvement Council. Prescriber-specific results will be confidentially provided to Medical Staff Support for use in the reappointment/recredentialing process.